Vaccination can also lower your chances of other serious shingles complications. For example, if it shows up on your face, ...

Sareen, PharmDMedically reviewed by Gurdeep S. Sareen, PharmD The second dose of Shingrix (recombinant zoster vaccine) may cause side effects that are worse than the first. The second dose is ...

New study reveals potential cognitive benefits of Shingrix vaccine. The shingles shot may offer protection against dementia, especially in women.

Shingrix grew 19% to £833 million in the quarter, backed up by solid performances for meningitis vaccines Bexsero and Menveo, which rose 34% to £218 million and 40% to £59 million, respectively.

Shingrix was hit hard in the first quarter as a result of the prioritisation of COVID-19 vaccination programmes in the US and other markets, with sales dropping almost 50% to £327 million, but ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

In this study, researchers from the University of Oxford compared the health records of people in the US who had the older Zostavax jab with a newer jab, called Shingrix, which is increasingly ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Shingrix sales reached 739 million pounds, down 7% at constant currency, with Arexvy sales of 188 million pounds, down 72%. Vaccine sales are expected to decrease at low-single-digit percent.

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation unjustified, leading to a "Strong Buy" rating. The company’s diversified ...

Based on the shingles incidence rate from the placebo arm North American cohort of ZOSTER-006, a Phase 3 trial of Shingrix, 10 of the 876 participants in the Phase 2 trial should have been diagnosed ...

Arexvy sales plunged 72 per cent to £188mn in the third quarter compared with the same period last year, while sales of its shingles vaccine Shingrix fell 7 per cent to £739mn. The UK drugmaker ...